Evidence map›Paper›PMID 35778969›Full record

ArticleGenes, chromosomes & cancer2022

Lateralized overgrowth with vascular malformation caused by a somatic PTPN11 pathogenic variant: Another piece added to the puzzle of mosaic RASopathies.

Alessandro Mussa, Antonella Turchiano, Simona Cardaropoli, Paola Coppo, Antonino Pantaleo, Rosanna Bagnulo, Carlotta Ranieri, Matteo Iacoviello, Antonella Garganese, Alessandro Stella and 6 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Genes, chromosomes & cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Alessandro MussaDepartment of Public Health and Pediatric Sciences, University of Torino, Torino, Italy.ORCID 0000-0003-2795-6013
Antonella TurchianoDivision of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", Bari, Italy.
Simona CardaropoliDepartment of Public Health and Pediatric Sciences, University of Torino, Torino, Italy.
Paola CoppoPediatric Dermatology, Regina Margherita Children's Hospital, Città della Salute e della Scienza di Torino, Torino, Italy.
Antonino PantaleoDivision of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", Bari, Italy.
Rosanna BagnuloDivision of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", Bari, Italy.
Carlotta RanieriDivision of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", Bari, Italy.
Matteo IacovielloDivision of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", Bari, Italy.
Antonella GarganeseUnit of Medical Genetics, Ospedale Consorziale Policlinico di Bari, Bari, Italy.
Alessandro StellaDivision of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", Bari, Italy.ORCID 0000-0002-9035-6267
Stefano Gabriele ValleroPediatric Onco-Hematology, Regina Margherita Children's Hospital, Città della Salute e della Scienza di Torino, Torino, Italy.
Daniele BertinPediatric Onco-Hematology, Regina Margherita Children's Hospital, Città della Salute e della Scienza di Torino, Torino, Italy.
Federica SantoroPathology Unit, Department of Medical Sciences, University of Torino, Torino, Italy.
Diana CarliDepartment of Public Health and Pediatric Sciences, University of Torino, Torino, Italy.
Giovanni Battista FerreroDepartment of Clinical and Biological Sciences, University of Torino, Orbassano, Italy.
Nicoletta RestaDivision of Medical Genetics, Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", Bari, Italy.ORCID 0000-0001-8640-5532
University of Bari Aldo Moro · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITUniversity of Turin · ITAzienda Universitaria Ospedaliera Consorziale - Policlinico Bari · ITOspedale Regina Margherita · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lateralized/segmental overgrowth disorders (LOs) encompass a heterogeneous group of congenital conditions with excessive body tissue growth. Documented molecular alterations in LOs mostly consist of somatic variants in genes of the PI3KCA/AKT/mTOR pathway or of chromosome band 11p15.5 imprinted region anomalies. In some cases, somatic pathogenic variants in genes of the RAS/MAPK pathway have been reported. We present the first case of a somatic pathogenic variant (T507K) in PTPN11 causing a LO phenotype characterized by severe lateralized overgrowth, vascular proliferation, and cerebral astrocytoma. The T507K variant was detected in DNA from overgrown tissue in a leg with capillary malformation. The astrocytoma tissue showed a higher PTPN11 variant allele frequency. A pathogenic variant in FGFR1 was also found in tumor tissue, representing a second hit on the RAS/MAPK pathway. These findings indicate that RAS/MAPK cascade overactivation can cause mosaic overgrowth phenotypes resembling PIK3CA-related overgrowth disorders (PROS) with cancer predisposition and are consistent with the hypothesis that RAS/MAPK hyperactivation can be involved in the pathogenesis of astrocytoma. This observation raises the issue of cancer predisposition in patients with RAS/MAPK pathway gene variants and expands genotype spectrum of LOs and the treatment options for similar cases through inhibition of the RAS/MAPK oversignaling.

Indexed as

AstrocytomaVascular MalformationsClass I Phosphatidylinositol 3-KinasesGenotypeHumansMutationPhenotypeProtein Tyrosine Phosphatase, Non-Receptor Type 11Class I Phosphatidylinositol 3-KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanastrocytomaFGFR1mosaicismovergrowthPTPN11RASopathies

Identifiers

PMID35778969
PMCPMC9542063
OpenAlexW4283778822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.